Difference between revisions of "Chronic myelomonocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''Use of this site is subject to you reading and agreeing with the terms set forth" to "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:200%"> Hello!<br> We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br> Please help us by filling it out!<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth") |
Warner-admin (talk | contribs) |
||
| Line 9: | Line 9: | ||
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]]. | ||
| − | + | {| class="wikitable" style="text-align:center; width:50%;" | |
| + | !colspan="2" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Section editor''' | ||
| + | |- | ||
| + | |style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.3|center]] | ||
| + | |<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big> | ||
| + | |- | ||
| + | |} | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 15:10, 13 January 2018
|
Hello! |
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
| Section editor | |
|---|---|
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN |
7 regimens on this page
10 variants on this page
|
Guidelines
International expert panel
- Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. (2017) PubMed
NCCN
First-line therapy
Azacitidine monotherapy
| back to top |
Regimen #1, 7 days
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine & Lenalidomide | Seems not superior |
| Azacitidine & Vorinostat | Seems not superior |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC/IV once per day on days 1 to 7
28-day cycles
Regimen #2, 5-2-2
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Drummond et al. 2014 | Phase II | ||
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine & Lenalidomide | Seems not superior |
| Azacitidine & Vorinostat | Seems not superior |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 IV once per day on days 1 to 5, 8 & 9
28-day cycle for at least 6 cycles, then continued for responders or SD until progression or intolerance.
References
- Drummond MW, Pocock C, Boissinot M, Mills J, Brown J, Cauchy P, Cross NC, Hartley S, Kell J, Szubert A, Cockerill PN, Bowen DT. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. 2014 Jul;28(7):1570-2. Epub 2014 Feb 26. link to original article contains verified protocol PubMed
- Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains verified protocol PubMed
Azacitidine & Lenalidomide
| back to top |
Regimen #1, 7 days of azacitidine
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine | Seems not superior |
| Azacitidine & Vorinostat | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC/IV once per day on days 1 to 7
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles
Regimen #2, 5-2-2 azacitidine
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine | Seems not superior |
| Azacitidine & Vorinostat | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC/IV once per day on days 1 to 5, 8 & 9
- Lenalidomide (Revlimid) 10 mg PO once per day on days 1 to 21
28-day cycles
References
- Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains verified protocol PubMed
Azacitidine & Vorinostat
| back to top |
Regimen #1, 7 days of azacitidine
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine | Seems not superior |
| Azacitidine & Lenalidomide | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC/IV once per day on days 1 to 7
- Vorinostat (Zolinza) 300 mg PO BID on days 3 to 9
28-day cycles
Regimen #2, 5-2-2 azacitidine
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Sekeres et al. 2017 (SWOG S1117) | Randomized Phase II, <20 pts in subgroup | Azacitidine | Seems not superior |
| Azacitidine & Lenalidomide | Not reported |
Chemotherapy
- Azacitidine (Vidaza) 75 mg/m2 SC/IV once per day on days 1 to 5, 8 & 9
- Vorinostat (Zolinza) 300 mg PO BID on days 3 to 9
28-day cycles
References
- Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. Epub 2017 May 9. link to original article contains verified protocol PubMed
Maintenance after first-line therapy
Azacitidine monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Grövdal et al. 2010 | Phase II |
Chemotherapy
- Azacitidine (Vidaza) 60 mg/m2 SC once per day on days 1 to 5
28-day cycles
References
- Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. Epub 2010 May 20. link to original article contains verified protocol PubMed content property of HemOnc.org